Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1

[1]  B. Chauffert,et al.  A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04) , 2019, Annals of Oncology.

[2]  P. Neven,et al.  The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 , 2019, JAMA oncology.

[3]  Alison Cave,et al.  Real‐World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe , 2019, Clinical pharmacology and therapeutics.

[4]  N. Sobhani,et al.  Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer , 2019, Cells.

[5]  Amy M. Sitapati,et al.  NCCN Guidelines Insights: Breast Cancer, Version 3.2018. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  W. Mackillop,et al.  Real-world data: towards achieving the achievable in cancer care , 2019, Nature Reviews Clinical Oncology.

[7]  Jacqueline Corrigan-Curay,et al.  Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness. , 2018, JAMA.

[8]  N S El Saghir,et al.  4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  A. Abernethy,et al.  Development and Validation of a High‐Quality Composite Real‐World Mortality Endpoint , 2018, Health services research.

[10]  Nancy A. Dreyer,et al.  Advancing a Framework for Regulatory Use of Real-World Evidence , 2018, Therapeutic innovation & regulatory science.

[11]  A. Abernethy,et al.  Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval. , 2018, The oncologist.

[12]  P. Neven,et al.  MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Hudis,et al.  MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer , 2017, Clinical Cancer Research.

[14]  Jian Du,et al.  Preclinical characterization of abemaciclib in hormone receptor positive breast cancer , 2017, Oncotarget.

[15]  S. Loi,et al.  Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. , 2016, The Lancet. Oncology.

[16]  Amy P Abernethy,et al.  Opportunities and challenges in leveraging electronic health record data in oncology. , 2016, Future oncology.

[17]  E. Perez,et al.  Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Piccart,et al.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Sung-Bae Kim,et al.  Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[20]  Kathleen A Cronin,et al.  US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. , 2014, Journal of the National Cancer Institute.

[21]  Chris Twelves,et al.  Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study , 2011, The Lancet.

[22]  David Miles,et al.  Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Rubin.  Bias Reduction Using Mahalanobis-Metric Matching , 1980 .

[24]  D. Rubin.  BIAS REDUCTION USING MAHALANOBIS METRIC MATCHING , 1978 .

[25]  A. Tutt,et al.  3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). , 2017, Breast.

[26]  Jens Hainmueller,et al.  Entropy Balancing for Causal Effects: A Multivariate Reweighting Method to Produce Balanced Samples in Observational Studies , 2012, Political Analysis.

[27]  J. Williams,et al.  A Review Document , 1998 .